What is Incyte's cash & equivalents?

Incyte (INCY) reported cash & equivalents of $3.46B in Q1 2026.

How has Incyte's cash & equivalents changed year-over-year?

Incyte's cash & equivalents increased by 78.2% year-over-year, from $1.94B to $3.46B.

What is the long-term trend for Incyte's cash & equivalents?

Over 5 years (2020 to 2025), Incyte's cash & equivalents has grown at a 15.4% compound annual growth rate (CAGR), from $1.51B to $3.1B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Incyte INCY Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers SquibbBMY

$9.57B-12.0%

PfizerPFE

$1.76B+18.8%

Celldex TherapeuticsCLDX

$35.73M+109%

Gilead SciencesGILD

$7.63B-3.8%

GeronGERN

$48.72M-12.2%

Protagonist TherapeuticsPTGX

$193.71M+38.7%

Other financials

Income statement

See full

Revenue$1.3B+20.9%

Gross profit$1.2B+19.2%

Operating income$301.1M+46.8%

Net income$303.3M+91.7%

EPS (diluted)$1.47+83.7%

Balance sheet

See full

Total debt$39.4M-8.6%

Total equity$5.6B+53.3%

Total assets$7.3B+27.7%

Cash flow

See full

Operating cash flow$369.4M+38.8%

CapEx$1.6M-43.5%

Free cash flow$367.7M+39.7%

Valuation

See full

Market cap$23.32B+74.2%

Enterprise value$19.89B+73.4%

P/E16.3×+0.9×

P/S4.4×+1.4×

Profitability

See full

Gross margin92.5%-0.2pp

Operating margin30%+26.1pp

Net margin26.7%+26.2pp

FCF margin28.2%+19.7pp

Returns & leverage

See full

Return on equity30.8%+30.4pp

Debt / equity0×0.0×

Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Incyte's cash & equivalents?: Incyte (INCY) reported cash & equivalents of $3.46B in Q1 2026.
How has Incyte's cash & equivalents changed year-over-year?: Incyte's cash & equivalents increased by 78.2% year-over-year, from $1.94B to $3.46B.
What is the long-term trend for Incyte's cash & equivalents?: Over 5 years (2020 to 2025), Incyte's cash & equivalents has grown at a 15.4% compound annual growth rate (CAGR), from $1.51B to $3.1B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.